#SFHS2614799AFrance Updates Reimbursement List for Weight-Management Medicines
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds six pharmaceutical products to France’s list of medicines reimbursed by social health insurance, but only for tightly defined adult weight-management cases. Coverage applies when structured nutrition care has failed, and the medicine is used alongside a low-calorie diet and increased physical activity. The reimbursement is limited to adults with severe obesity: BMI of at least 40 without another condition, or BMI of at least 35 with specified health complications such as type 2 diabetes, treated hypertension, serious lipid disorder, NASH or liver fibrosis, sleep apnea, severe obesity-related asthma, chronic disabling joint or back disease, fertility treatment needs, kidney disease, or other listed conditions. Healthcare providers will need to document eligibility and, in several cases, obtain specialist input.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds six pharmaceutical products to the list of medicines reimbursed by French social health insurance
- Limits reimbursement to adult weight-management treatment after failed structured nutrition care
- Sets detailed BMI, comorbidity, and specialist-review conditions for coverage
Obligations
What this law requires
Health insurance reimbursement for the listed pharmaceutical specialties must be granted only for adult patients whose well-conducted nutritional care has failed, defined as less than 5% weight loss after six months.
The listed medicines must be reimbursed only when used alongside a low-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance.
Reimbursement must be limited to adults with an initial BMI of at least 40 kg/m² without comorbidity, or an initial BMI of at least 35 kg/m² with at least one listed comorbidity.
For patients with BMI of at least 35 kg/m², reimbursement eligibility must be supported by a listed comorbidity such as type 2 diabetes, treated hypertension, qualifying severe hypertriglyceridemia, NASH or liver fibrosis, sleep apnea with IAH ≥ 15/h, severe obesity-related asthma, chronic disabling joint or back disease, fertility-treatment needs, kidney disease, polycystic ovary syndrome, or disabling urinary incontinence meeting the specified conditions.
Isolated hepatic steatosis must not be treated as a qualifying comorbidity for reimbursement of obesity drug treatment under this order.